top of page
.png){kind=small}
AF: A Novel Compound to Boost Sperm Motility
AF is a proprietary compound that enhances human sperm motility by more than 700% on contact — offering a first-in-class solution to a longstanding gap in male fertility care. Aqua Fem is offering full IP rights to this asset for acquisition.
IP & DEAL STRUCTURE
Aqua Fem Is Seeking a Strategic Buyer
We are offering a full IP sale of AF, including:​
​
-
Composition-of-matter and method-of-use patents
-
Formulation know-how and supporting data
-
Optional transitional support and co-development consulting
Our preference is for a full asset acquisition, though we are open to flexible structuring by indication, geography, or use case.
WHY AF MATTERS NOW
A Critical Need. A Ready Solution.
Male infertility contributes to nearly 50% of all infertility cases — yet current solutions are limited, inconsistent, or unavailable. AF offers a novel mechanism of action, a strong safety profile, and broad application potential across clinical and consumer markets.
700% increase in sperm motility
Zero observed DNA damage
or acrosome disruption
IP protected through 2046
Projected $41B fertility market by 2028
SEE IT IN ACTION
AF's Novel Mechanism of Action Supercharges
Sperm Motility by more than 700%
APPLICATIONS
A Scalable Asset with Multichannel Potential
AF can be developed for use in:
ART Clinics
As an additive to sperm washing media in IVF and IUI
Consumer Products
In lubricants or conception aids for at-home use
Diagnostics & Research
For sperm function assays and fertility testing
PRECLINICAL DATA HIGHLIGHTS
Efficacy and Safety Profile
Extensive testing demonstrates AF’s efficacy and compatibility with reproductive tissue:​
CASA: Immediate and sustained motility increase
No DNA fragmentation or cellular degradation
Normal sperm morphology and acrosome integrity
No toxicity in mouse vaginal tissue studies
bottom of page